Precision in Practice

Using Minimally Invasive Laser Ablation

Aiming for the precise

The challenges in healthcare are many. At CLS we are committed to developing better therapies for use in cancer care and neurosurgery. We do this by providing tools for precise tissue ablation using heat generated by laser light. Our close collaboration with healthcare professionals ensures our products meet their requirements and seamlessly fits into hospital workflows. This enables more patients to be treated based on their specific diagnosis and needs. Carefully precise.

Focal therapy in localized prostate cancer

Focal therapy using laser ablation is a growing treatment option for patients with prostate cancer. It is an effective method that treats the tumor locally without damaging healthy tissue. The procedure is minimally invasive and thus gentle on the patient, who typically can return quickly to normal life. 

brain-therapy


Careful therapy of brain lesions

A tumor or epileptogenic foci in the brain means major challenges – for the patient and for healthcare. When using laser ablation in neurosurgery the lesion is directly targeted and treated with high precision. The treatment spares healthy tissue and causes less side effects than surgery and chemotherapy.

Immune stimulating laser ablation – using new hot technology

The thermal effects on cells depend mainly on two factors – temperature and time. Research has shown that moderate heating of cancerous tumor cells during a long time will not only kill the targeted tumor itself, but also activate the immune system to attack cancer cells throughout the body.

Integrated therapy systems for high precision laser ablation

Our driving force is to design and develop tools for treatment of severe diseases, such as cancer, in a precise and careful way. It is from this perspective we have developed CLS TRANBERG® Thermal Therapy Systems – seamlessly integrated systems for laser ablation, with several options for real time monitoring and control of the treatment.

Annual General Meeting 2022

Pipeline

Research is just the beginning - and that is where it all began for CLS. We are now running various clinical studies to develop new therapies in the fight against serious diseases such as cancer.

Investor relations

CLS is listed on Nasdaq First North Growth Market. Our aim is to provide relevant and transparent information for analysts, investors and media with the latest financial reports, events, news and the development of CLS’s share.

News and insights

1 February, 2023

How it Works – Learn more about Laser Ablation in Neurosurgery

Since CLS´s laser ablation system for neurosurgery was cleared by the FDA in September last year development has progressed rapidly. But how does it actually work? We explain in this news post.

Read more
19 January, 2023

Press Release from Skåne University Hospital on the Ongoing Study using CLS Products for Neurosurgery inside the MRI Camera

Today Skåne University Hospital (SUS) published a press release with the title “Laser surgery in a magnetic camera – new help for patients with brain tumors”. The PM provides an insight to the ongoing study using CLS products for laser surgery inside a MRI camera. The hospital writes that doctors now can treat patients with hard-to-reach brain tumors that medical care was previously unable to help. So far two patients with brain tumors have been successfully treated as part of the study.

Read more
21 December, 2022

Christmas greeting from CLS - We wish you all a very Happy Holiday season and look forward to a tremendous 2023!

At CLS we can look back on an exciting year where we have made significant progress towards our vision that laser ablation will be introduced as standard treatment in focal therapy and as an alternative to traditional surgery and, in the longer term, as a complementary systemic treatment of metastasized cancer.

Read more

Sign up for our
newsletter

Make sure you get all the exciting information about CLS’ progress on an ongoing basis.

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!


Please choose your country or region

Global
US